Diagnostic and prognostic value of miR-106a in colorectal cancer
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1543 views | HTML 1984 views | ?
Haibin Hao1,*, Laipeng Liu1,*, Dong Zhang1,*, Chao Wang1, Guangfeng Xia1, Fuping Zhong1, Xiaoyun Hu1
1Department of General Surgery, Second Affiliated Hospital of Nanchang University, Nanchang, China
*These authors have contributed equally to this work and should be considered as co-first authors
Xiaoyun Hu, email: [email protected]
Keywords: miR106a, colorectal cancer, CRC, diagnosis, prognosis
Received: June 29, 2016 Accepted: November 22, 2016 Published: December 1, 2016
We sought to systematically evaluate the diagnostic and prognostic value miR106a in patients with colorectal cancer (CRC). An original study was conducted to explore correlations between tissue miR106a levels and outcomes for 138 patients diagnosed with CRC. To explore the diagnostic performance of miR106a, eligible studies were identified from medical databases from China and abroad. Based on these results, 15 studies (including our original study) were pooled and included in a meta-analyses. The pooled sensitivity, specificity, and diagnostic odds ratios of miR106a were 0.53 (95% confidence interval (CI): 0.49–0.57), 0.85 (95% CI: 0.82–0.88), and 7.22 (95% CI: 3.17–16.44) for diagnosis of CRC, and the area under the curve (AUC) for miR106a when diagnosing CRC was 0.72. Patients with higher expression of tissue miR106a had poor overall survival (pooled hazard ratio (HR): 1.50; 95% CI: 1.02–2.20), but not disease-free survival (pooled HR: 1.03; 95% CI: 0.40–2.65). Overexpression of miR106a may predict superior metastasis-free survival (pooled HR: 0.65; 95% CI: 0.33–1.27), but the effect was not significant in this study (p = 0.21).
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.